TOKYO, Jun 17 (Pulse News Wire) – HEALIOS K.K. (4593.T) announced today that its board of directors approved the issuance of stock options to CEO Atsunori Kagiya .
The move follows the company's global expansion plans, particularly focusing on the development of treatments for acute respiratory distress syndrome (ARDS). The stock options will vest based on achieving significant milestones such as securing conditional approval for HLCM051 in Japan and reaching sales targets exceeding ¥1 billion annually. Under the agreement, Kagiya will receive options to purchase up to 1.5 million shares at a price set below the market value on the day prior to the resolution, ensuring alignment with industry standards.
The exercise conditions include hitting annual revenue targets and key regulatory approvals, reflecting the company’s commitment to long-term growth and shareholder value enhancement. The funds raised through the issuance will support ongoing research and development activities, including the Phase III trial for HLCM051 in the United States and preparations for conditional approval in Japan. Additionally, the company aims to capitalize on continuous sales from cell culture supernatant and potential licensing deals, contributing to sustained revenue growth.
🟡 Confidence: Standard AI-translated content.